Halozyme Therapeutics, Inc. (HALO) stock price escalated 5.43% to finalize at $14.17 throughout previous buying and selling session. A total of 1.58 million shares exchanged at hands and its average trading volume is standing at 1.18 million shares. Important factors to focus when evaluating a stock’s present and future value are the 52 week price high and low levels. Shares of Halozyme Therapeutics, Inc. (HALO) are trading -6.78% downward from the 52-week high mark and 84.03% above from the fifty two-week low mark.
Taking a glance at past performance, we will examine different up or down moving trends about HALO. The stock added 10.27% beyond one week and climbed 0.07% during previous one month session. The stock went down -1.67% at some stage in past quarter. Inside the closing six months period the stock’s performance raised 25.96% while overall yearly performance gained 66.31%. The Company’s year to date (YTD) performance is now positive at 43.42%.
Halozyme Therapeutics, Inc. (HALO) stock price away from 20 day simple moving average surged at 11.21% while its distance from 50 day simple moving average raised 7.07% along with 16.92% above away from two hundred simple moving averages. On technical aspect, moving averages may help to distinguish path of dispositions, and they may also be used to set degrees of support and resistance. Tracking the stock price in relation to moving averages as well as highs and lows for the year might assist with evaluating future stock performance.
The Stock has Weekly volatility of 3.91% and monthly volatility of 3.88%. Tracking most recent quarter period, Price to cash per share ration is at 10.75. Beta value of the stock is marked at 2.22. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security’s price will be more volatile than the market. The company has a Return on Assets (ROA) of -43.50%. Presently, it has a Return on Equity (ROE) of 499.10% and Return on Investment (ROI) of -45.80%. Relative strength index (RSI-14) for Halozyme Therapeutics, Inc. (HALO) is at 66.69. Average true range (ATR-14) of the company is at 0.56.